TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01084057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ixabepilone
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ixabepilone
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT00664352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mannose-6-Phosphate (Juvidex)
Description: * 100µL of 300mM (8.46 mg/100μL) Juvidex will be injected intradermally into each cm2 of one 3cm2 donor site and into the 0.5cm border around the donor site no more than 20 minutes before graft harvest (total dose 750µL). A further 300µL of 300mM (8.46 mg/100μL) Juvidex will be applied topically within 30 minutes of graft harvest and 24 hours after graft harvest.~* 100µL of placebo will be injected intradermally into each cm2 of the other 3cm2 donor site and into the 0.5cm border around the donor site no more than 20 minutes before graft harvest (total dose 750µL). A further 300µL of placebo will be applied topically within 30 minutes of graft harvest and 24 hours after graft harvest.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mannose-6-Phosphate (Juvidex)
Description: * 100µL of 600mM(16.93 mg/100μL) Juvidex will be injected intradermally into each cm2 of one 3cm2 donor site and into the 0.5cm border around the donor site no more than 20 minutes before graft harvest (total dose 750µL). A further 300µL of 600mM (16.93 mg/100μL) Juvidex will be applied topically within 30 minutes of graft harvest and 24 hours after graft harvest.~* 100µL of placebo will be injected intradermally into each cm2 of the other 3cm2 donor site and into the 0.5cm border around the donor site no more than 20 minutes before graft harvest (total dose 750µL). A further 300µL of placebo will be applied topically within 30 minutes of graft harvest and 24 hours after graft harvest.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mannose-6-Phosphate (Juvidex)
Description: * 300µL of 300mM (8.46 mg/100μL) Juvidex will be applied topically to one 3cm2 donor site within 30 minutes of graft harvest and 24 hours after graft harvest.~* 300µL of placebo will be applied topically to the other 3cm2 donor site within 30 minutes of graft harvest and 24 hours after graft harvest.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mannose-6-Phophate (Juvidex)
Description: * 300µL of 600mM (16.93 mg/100μL) Juvidex will be applied topically to one 3cm2 donor site within 30 minutes of graft harvest and 24 hours after graft harvest.~* 300µL of placebo will be applied topically to the other 3cm2 donor site within 30 minutes of graft harvest and 24 hours after graft harvest.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: * 100µL of placebo will be injected intradermally into each cm2 of one 3cm2 donor site and into the 0.5cm border around the donor site no more than 20 minutes before graft harvest (total dose 750µL). A further 300µL of placebo will be applied topically within 30 minutes of graft harvest and 24 hours after graft harvest.~* Standard Care (moist wound healing dressings alone) will be applied to the other 3cm2 donor site.
Study: NCT02315144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TV48108
Description: TV48108 15, 60, 120 μg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TV48108
Description: TV48108 15, 60, 120 μg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TV48108
Description: TV48108 15, 60, 120 μg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TV48108
Description: TV48108 15, 60, 120 μg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator
Study: NCT01575418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rectal formulation (RF) of tenofovir 1% gel
Description: The RF is translucent colorless viscous gel formulation containing 1% (w/w) of tenofovir (PMPA) formulated in purified water with EDTA, glycerin, methylparaben, propylparaben, carbopol, sodium carboxy methyl cellulose, and pH adjusted to 7. The RF is close to isoosmolar with an osmolality of 479 mOsmol/kg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal formulation (VF) of tenofovir 1% gel
Description: The original VF is a transparent, viscous gel formulation containing 1% (weight/ weight or w/w) of tenofovir (PMPA, 9-\[(R)-2-(phosphonomethoxy)propyl\]adenine monohydrate), formulated in purified water with edetate disodium, citric acid, glycerin, methylparaben, propylparaben, hydroxyethylcellulose, and pH adjusted to 4-5. This formulation has been used in all clinical trials (vaginal, penile, and rectal) of tenofovir 1% gel to date.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reduced glycerin vaginal formulation (RGVF) of tenofovir 1% gel
Description: Modified slightly from the original VF formulation, the RGVF has a lower glycerin content than the VF and a significantly reduced osmolality (836 or 846 versus 3111 mOsmol/kg). Lowering glycerin content lowered the viscosity, so the HEC concentration was increased by 10% (a change considered to be insignificant). The amount of parabens was increased by 10% each to improve the antimicrobical effectiveness. The RGVF formulation with 2.75% HEC was used in MTN-007 (CONRAD IND 73,382; currently enrolling), which is the only clinical study of this formulation. The RGVF formulation has since been modified to increase the viscosity.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiolabeling of study drugs and semen
Description: Study products (i.e. the gel formulations) will be radiolabeled with 111In-DTPA, an FDA-approved radiopharmaceutical commonly used in diagnostic nuclear medicine studies. The delivered dose per gel study product will be approximately 100 microCuries (µCi) to allow sufficient visualization for the imaging period.~Autologous whole semen collected from the participants at designated visits will be radiolabeled with a delivered dose of approximately 500 microCuries (µCi) of 99mTc-sulfur colloid, also an FDA-approved radiopharmaceutical commonly used in diagnostic nuclear studies. The study team at JHU has extensive experience administering these radiopharmaceuticals rectally. Both of these radiopharmaceuticals will be prepared and delivered by a commercial radiopharmacy and mixed by the study investigators with the respective gel and whole semen vehicles.~The study product and autologous whole semen will be loaded into calibrated syringes with luer lock adapter for dosing.
Study: NCT01852461

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Poractant alfa
Description: porcine lung extract, initial dosing is 200 mg/kg (2.5 mL/kg) and repeated dosing is given at 100 mg/kg (1.25 mL/kg) every 12 hours, up to maximum of two additional doses when indicated
Study: NCT03137043

Intervention type: OTHER
Intervention: Questionnaire
Description: Subjects will be given an Electronic Case Report Form (eCRF) with a series of questionnaire such as Asthma Control Test, Morisky-Green Questionnaire and St George's Respiratory Questionnaire.

Intervention type: OTHER
Intervention: Questionnaire
Description: Subjects will be given an Electronic Case Report Form (eCRF) with a series of questionnaire such as Asthma Control Test, Morisky-Green Questionnaire and St George's Respiratory Questionnaire.

Intervention type: OTHER
Intervention: Software of Big Data
Description: Software of big data is a powerful data treatment algorithm works closely with Spanish Data Protection Agency as an example on how to reuse clinical information without conflicting with necessary data privacy. The system will process a vast amount of information (big data), so that the impact of random errors will be minimized.

Intervention type: OTHER
Intervention: Software of Big Data
Description: Software of big data is a powerful data treatment algorithm works closely with Spanish Data Protection Agency as an example on how to reuse clinical information without conflicting with necessary data privacy. The system will process a vast amount of information (big data), so that the impact of random errors will be minimized.
Study: NCT02132832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buspirone
Description: Buspirone is an anxiolytic compound marked by modulation of both 5-HT1A and D3 receptors. Buspirone is administered orally twice per day (9:00 AM and 6:00 PM) for 3 weeks. 10 mg buspirone is administered on days 1-4, then the dose is increased by 10 mg every 3 days to a maximum of 40 mg buspirone on days 10-19.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is administered orally twice per day (9:00 AM and 6:00 PM) for 3 weeks.
Study: NCT05338125

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Micro-electrode measurement
Description: Electrophysiological measurement with single-unit micro-electrode
Study: NCT03461770

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CPAP
Description: Patients will receive general anesthesia induction with CPAP at 5 cmH20 via face mask with a circular system. CPAP will use before extubation.The air-test will perform during anesthesia with transitory decreases inspired fraction of oxygen to 0.21 over a 5 min period. Recruitment maneuver will be perform if the air test is positive, ( SpO2 is ≤ 96%)
Study: NCT01849640

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DHA-piperaquine and Primaquine
Description: Subject will be enrolled in open label fashion to a 3-day treatment course of DHA-piperaquine (DP) by directly observed therapy (DOT, all patients will receive a total of 9 tablets containing 40mg DHA and 320mg of piperaquine in divided doses at 0, 24 and 48 hours (3 tablets once per day) for the 3 day course. At completion of DP treatment volunteers will be randomized in an open label fashion to receive a single 45 mg dose of primaquine or no therapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DHA-piperaquine and Primaquine
Description: Subject will be enrolled in open label fashion to a 3-day treatment course of DHA-piperaquine (DP) by directly observed therapy (DOT, all patients will receive a total of 9 tablets containing 40mg DHA and 320mg of piperaquine in divided doses at 0, 24 and 48 hours (3 tablets once per day) for the 3 day course. At completion of DP treatment volunteers will be randomized in an open label fashion to receive a single 45 mg dose of primaquine or no therapy.
Study: NCT04148989

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Code Sepsis protocol (full implementation)
Description: Implementation of a coordinated, structured, multidisciplinary team-based protocol for initial evaluation and treatment of ED patients with suspected sepsis.
Study: NCT02251769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipranavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-Fat Test Meal
Study: NCT03015129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Study: NCT01102764

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telemedicine
Description: Prolonged Exposure (PE) therapy provided at patients house via telemedicine

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: In Person
Description: PE therapy delivered in person at the VAMC
Study: NCT04615195

Intervention type: OTHER
Intervention: cries 13 questionnaire
Description: Participant will be contacted by telephone by a clinical research assistant to answer the CRIES 13 questionnaire.~In large families, the CRIES-13 of the holder of parental authority and of the child will be applied for each of them whose age corresponds to the inclusion criteria.
Study: NCT03033940

Intervention type: RADIATION
Intervention: Observational use of fluoroscopy

Intervention type: RADIATION
Intervention: Observational use of fluoroscopy
Study: NCT03151070

Intervention type: OTHER
Intervention: QVLM Intervention package
Description: QVLM intervention package consists of 3 simultaneous interventions:~* Social marketing to promote insitutional deliveries.~* PRONTO training to public health personnel~* Improve interaction with traditional birth attendants

Intervention type: OTHER
Intervention: QVLM Intervention package
Description: QVLM intervention package consists of 3 simultaneous interventions:~* Social marketing to promote insitutional deliveries.~* PRONTO training to public health personnel~* Improve interaction with traditional birth attendants

Intervention type: OTHER
Intervention: QVLM Intervention package
Description: QVLM intervention package consists of 3 simultaneous interventions:~* Social marketing to promote insitutional deliveries.~* PRONTO training to public health personnel~* Improve interaction with traditional birth attendants

Intervention type: OTHER
Intervention: QVLM Intervention package
Description: QVLM intervention package consists of 3 simultaneous interventions:~* Social marketing to promote insitutional deliveries.~* PRONTO training to public health personnel~* Improve interaction with traditional birth attendants

Intervention type: OTHER
Intervention: QVLM Intervention package
Description: QVLM intervention package consists of 3 simultaneous interventions:~* Social marketing to promote insitutional deliveries.~* PRONTO training to public health personnel~* Improve interaction with traditional birth attendants

Intervention type: OTHER
Intervention: QVLM Intervention package
Description: QVLM intervention package consists of 3 simultaneous interventions:~* Social marketing to promote insitutional deliveries.~* PRONTO training to public health personnel~* Improve interaction with traditional birth attendants
Study: NCT03214653

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Subjects were given target-controlled infusion of propofol using Schinder technique effect mode with the administration of maintenance agent was adjusted by the depth of sedation using bispectral index monitor with target of 45-50

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Subjects were given sevoflurane 1,5-2% as maintenance agent of anesthesia.
Study: NCT00963612

Intervention type: PROCEDURE
Group type: OTHER
Intervention: BOLD MRI test
Description: Additional MR pulse sequence performed on BOLD MRI is expected to increase the regular scan time by an additional 5-10 minutes. No intravenous contrast is required for BOLD acquisition.
Study: NCT02145338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrofurantoin or Trimethoprim or Cefalexin
Description: Antibiotic prophylaxis

Intervention type: OTHER
Group type: OTHER
Intervention: No prophylaxis
Description: Discrete treatment courses of antibiotics as indicated by symptoms or signs of UTI.
Study: NCT00250549

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Post test video
Description: We compared the educational effectiveness of a 15-minute posttest counseling video with the normal practice of a session with an HIV counselor.Patients in the experimental group watched an HIV posttest educational video.
Study: NCT02194504

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary advice, Western
Description: Dietary advice, guided by professional dieticians. Caloric restricted (-30en%) diet with Western type nutrient composition (SFA, carbohydrates, sugars, fruit juice, meat, dairy)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary advice, Targeted
Description: Dietary advice, guided by professional dieticians. Caloric restricted (-30en%) diet with nutrient composition aiming at an improvement in organ health and a reduction in liver fat (PUFA, fish, soy protein, whole grain)
Study: NCT00968825

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin Type A
Description: RT001 (Botulinum Toxin Type A Topical Gel) Dose D applied topically at Baseline (Day 0) to the lateral canthal lines

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (Dose E) applied topically at Baseline (Day 0) to the lateral canthal lines
Study: NCT03390959

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive Training
Description: Individuals in the Trained Group will perform the training twice a week for 45 minutes and perform for a period of 12 weeks.~The training is divided into a pre-training phase where general hip dissociation exercises and simple stretching of the hip flexor and extensor muscle groups, knee, foot and paravertebral are performed.~The second phase is the proprioceptive training, where it will involve training of balance, sensitivity and proprioception, being used a circuit composed of 15 stations, whose time of stay in each station is 2 minutes.~And finally the third stage are relaxation exercises, performed with breathing exercises associated with slow active movements of the joints.

Intervention type: OTHER
Group type: OTHER
Intervention: Control Group
Description: Will not be submitted to any physical intervention. It continues in your daily life with only phone monitoring.
Study: NCT00376077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone and IVIG
Description: Combination therapy (IV MP (Solu-Medrol®, Upjohn) 30 mg/kg (max. 1 g) over 1 hour followed by IVIG 1 g/kg (Gamunex Immune Globulin Intravenous \[Human\], 10%; Bayer)\* x 1 dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo and IVIG
Description: Placebo followed by IVIG 1 g/kg (Gamunex Immune Globulin Intravenous \[Human\], 10%; Bayer)\* x 1 dose
Study: NCT00835653

Intervention type: PROCEDURE
Intervention: median nerve block
Description: median nerve block performed under echographic guidance

Intervention type: PROCEDURE
Intervention: median nerve block
Description: median nerve block performed under echographic guidance
Study: NCT01408420

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MAP > 60 mmHg
Description: During heart surgery a blood pressure with a MAP \> 60 mmHg during extracorporeal circulation is used.
Study: NCT03129126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LP-10
Description: Intravesical tacrolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LP-10
Description: Intravesical tacrolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LP-10
Description: Intravesical tacrolimus
Study: NCT02922023

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ambulatory blood pressure monitor (ABPM)
Description: ABPM allows providers to obtain blood pressure readings over a 24 hour period, to assess blood pressure at night to determine dipping status, and to evaluate the efficacy of anti-hypertensive therapy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chronotherapy
Description: Chronotherapy group will receive a shift in the timing of one of their antihypertensive medications to nighttime dosing without consulting their ABPM results.
Study: NCT03560752

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multi-peptide CMV-Modified Vaccinia Ankara Vaccine
Description: Given via injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multi-peptide CMV-Modified Vaccinia Ankara Vaccine
Description: Given via injection
Study: NCT00233974

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET (positron emission tomography)
Description: Following conventional segmental mastectomy with or without needle localization, the patient will then undergo intraoperative PET-probe evaluation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET (positron emission tomography)
Description: Following conventional segmental mastectomy with or without needle localization, the patient will then undergo intraoperative PET-probe evaluation
Study: NCT03808701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCT200
Description: Recombinant Anti-EGFR Monoclonal Antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCT200
Description: Recombinant Anti-EGFR Monoclonal Antibody
Study: NCT03535831

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-DCFPyL
Description: The purpose of this study is to determine if use of 18F-DCFPyL would increase the detection of lesions and to better inform your oncologist on the best method of treatment for your disease.
Study: NCT02594657

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pedal rate on 50 RPM
Description: All measurements are performed in two pedalling situations. The two frequencies used will be 50 and 80 RPM. For each subject the running order (50 and 80, 80 and 50) is randomly determined
Study: NCT01575418

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiolabeling of study drugs and semen
Description: Study products (i.e. the gel formulations) will be radiolabeled with 111In-DTPA, an FDA-approved radiopharmaceutical commonly used in diagnostic nuclear medicine studies. The delivered dose per gel study product will be approximately 100 microCuries (µCi) to allow sufficient visualization for the imaging period.~Autologous whole semen collected from the participants at designated visits will be radiolabeled with a delivered dose of approximately 500 microCuries (µCi) of 99mTc-sulfur colloid, also an FDA-approved radiopharmaceutical commonly used in diagnostic nuclear studies. The study team at JHU has extensive experience administering these radiopharmaceuticals rectally. Both of these radiopharmaceuticals will be prepared and delivered by a commercial radiopharmacy and mixed by the study investigators with the respective gel and whole semen vehicles.~The study product and autologous whole semen will be loaded into calibrated syringes with luer lock adapter for dosing.
Study: NCT02594657

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pedal rate on 80 RPM
Description: All measurements are performed in two pedalling situations. The two frequencies used will be 50 and 80 RPM. For each subject the running order (50 and 80, 80 and 50) is randomly determined
Study: NCT00770887

Intervention type: PROCEDURE
Intervention: Self administration
Description: Subjects will self administer injections of 104 mg of the subcutaneous formulation of depot medroxyprogesterone acetate (depo-subQ provera 104).